ArticleDiabetes & vascular disease research
Predictive value of lncRNA DBH-AS1 for cardiovascular events in patients with type 2 diabetes mellitus with coronary heart disease.
Article in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe frequency of type 2 diabetes mellitus (T2DM) is rising annually. Coronary heart disease (CHD) is a prevalent complication affecting individuals with T2DM.
objectiveThe aim of this investigation was to assess the level of DBH-AS1 in T2DM with CHD, and to determine its potential role in forecasting the occurrence of significant cardiovascular events.
methodsThe DBH-AS1 levels were detected by qRT-PCR. The diagnostic value of DBH-AS1 was assessed through receiver operating characteristic (ROC) curve analysis. Logistic regression was conducted to identify the risk factors for cardiovascular events among patients with T2DM with CHD. Cell proliferation was detected by Cell Counting Kit-8 (CCK-8) assay, apoptosis was detected by flow cytometry, and the concentration of inflammatory factors was detected by Enzyme Linked Immunosorbent (ELISA) kit.
resultsDBH-AS1 was down-regulated in serum of both T2DM with CHD and cardiovascular events patients. Of the cardiovascular events that occurred, major events included recurrent angina (20%), cardiovascular death (7.5%), acute myocardial infarction (23.75%), severe arrhythmia (22.50%), acute heart failure (18.75%) and stroke (7.5%). And DBH-AS1 had a predictive value for each adverse of cardiovascular events. DBH-AS1 regulated the expression of miR-483-5p and affected the proliferation, apoptosis, and secretion of inflammatory factors of HCAECs.
conclusionDBH-AS1 may serve as a predictor for the occurrence of cardiovascular events in T2DM with CHD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.